A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn, Hee Kyung | - |
dc.contributor.author | Jung, Minkyu | - |
dc.contributor.author | Sym, Sun Jin | - |
dc.contributor.author | Shin, Dong Bok | - |
dc.contributor.author | Kang, Shin Myung | - |
dc.contributor.author | Kyung, Sun Young | - |
dc.contributor.author | Park, Jeong-Woong | - |
dc.contributor.author | Jeong, Sung Hwan | - |
dc.contributor.author | Cho, Eun Kyung | - |
dc.date.available | 2020-02-28T16:45:58Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2014-08 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/12444 | - |
dc.description.abstract | Genexol-PM is a Cremorphor EL (CrEL)-free polymeric micelle formulation of paclitaxel that allows higher-dose administration with less hypersensitivity. This study was designed to evaluate the efficacy and safety of Genexol-PM and gemcitabine combination in advanced non-small cell lung cancer patients as a first-line treatment. This is a prospective, single-arm, single-center phase II study. Patients with advanced NSCLC received Genexol-PM at 230 mg/m(2) on day 1 and gemcitabine 1,000 mg/m(2) on day 1 and day 8 of a 3-week cycle. Six cycles of chemotherapy were planned unless there was disease progression. The primary endpoint was overall response rate. Forty-three patients received the study drugs with a median of 4 cycles per patient (range 1-6). The overall response rate was 46.5 %. The median progression-free survival was 4.0 months (95 % CI 2.0-6.0 months), and median overall survival was 14.8 months (95 % CI 9.1-20.5 months). The most common toxicities were anemia (n = 29, 67 %), asthenia (n = 17, 40 %), myalgia (n = 16, 37 %), peripheral neuropathy (n = 15, 35 %), and diarrhea (n = 12, 30 %). The most common grade 3/4 adverse events were neutropenia (n = 7, 16 %) and pneumonia (n = 5, 12 %). Two patients died of pneumonia and dyspnea. CrEL-free paclitaxel in combination with gemcitabine demonstrated favorable antitumor activity with little emetogenicities in non-small cell lung cancer patients. However, frequent grade 3/4 toxicities were observed, and safety should be evaluated thoroughly in future studies. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.subject | POLYMERIC MICELLE FORMULATION | - |
dc.subject | COOPERATIVE-ONCOLOGY-GROUP | - |
dc.subject | CREMOPHOR-FREE | - |
dc.subject | CHEMOTHERAPY | - |
dc.subject | CARBOPLATIN | - |
dc.subject | CISPLATIN | - |
dc.subject | REGIMENS | - |
dc.subject | PLATINUM | - |
dc.title | A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000339825000007 | - |
dc.identifier.doi | 10.1007/s00280-014-2498-5 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.74, no.2, pp.277 - 282 | - |
dc.identifier.scopusid | 2-s2.0-84907599028 | - |
dc.citation.endPage | 282 | - |
dc.citation.startPage | 277 | - |
dc.citation.title | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.citation.volume | 74 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Ahn, Hee Kyung | - |
dc.contributor.affiliatedAuthor | Jung, Minkyu | - |
dc.contributor.affiliatedAuthor | Sym, Sun Jin | - |
dc.contributor.affiliatedAuthor | Shin, Dong Bok | - |
dc.contributor.affiliatedAuthor | Kang, Shin Myung | - |
dc.contributor.affiliatedAuthor | Kyung, Sun Young | - |
dc.contributor.affiliatedAuthor | Park, Jeong-Woong | - |
dc.contributor.affiliatedAuthor | Jeong, Sung Hwan | - |
dc.contributor.affiliatedAuthor | Cho, Eun Kyung | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Non-small cell lung cancer | - |
dc.subject.keywordAuthor | Gemcitabine | - |
dc.subject.keywordAuthor | Paclitaxel | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Genexol-PM | - |
dc.subject.keywordPlus | POLYMERIC MICELLE FORMULATION | - |
dc.subject.keywordPlus | COOPERATIVE-ONCOLOGY-GROUP | - |
dc.subject.keywordPlus | CREMOPHOR-FREE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | CARBOPLATIN | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | REGIMENS | - |
dc.subject.keywordPlus | PLATINUM | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.